Item 1.01 Entry into a Material Definitive Agreement.
On
Pursuant to the Amendment (and as a result of the termination of the Amended and
Restated Collaboration Agreement, dated
The foregoing description of the Amendment and the transactions contemplated thereby does not purport to be complete and is qualified in its entirety by reference to the Amendment, which is filed as Exhibit 10.1 hereof and which is incorporated herein by reference.
Item 1.02 Termination of a Material Definitive Agreement.
On
Item 9.01 Financial Statements and Exhibits.
(d) Exhibits.
10.1 Amendment No. 3 to the Exclusive License and Collaboration Agreement, datedApril 21, 2017 , by and betweenAmgen Inc. andNovartis Pharma AG (portions of the exhibit have been omitted because they are both (i) not material and (ii) is the type of information that the Company treats as private or confidential.) 104 Cover Page Interactive Data File (embedded within the Inline XBRL document). 1 SeeAmgen 's Annual Report on Form 10-K for the year endedDecember 31, 2020 , Part IV-Note 19, Contingencies and commitments, to the Consolidated Financial Statements; and Notes 13 and 14, Contingencies and commitments, to the condensed consolidated financial statements inAmgen 's Quarterly Report on Form 10-Q for the periods endedJune 30, 2021 andSeptember 30, 2021 , respectively. 2 SeeAmgen 's Current Report on Form 8-K filed onApril 24, 2017 ; and Exhibits 10.41 through 10.43, and 10.39 inAmgen 's Quarterly Reports on Form 10-Q for the quarters endedJune 30, 2017 andJune 30, 2021 , respectively.
--------------------------------------------------------------------------------
© Edgar Online, source